Catalyst Pharmaceuticals Files 8-K
Ticker: CPRX · Form: 8-K · Filed: Nov 6, 2024 · CIK: 1369568
| Field | Detail |
|---|---|
| Company | Catalyst Pharmaceuticals, Inc. (CPRX) |
| Form Type | 8-K |
| Filed Date | Nov 6, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-filing, 8-K, regulatory
Related Tickers: CPRX
TL;DR
Catalyst Pharma filed an 8-K on Nov 6, 2024. Standard corporate update.
AI Summary
Catalyst Pharmaceuticals, Inc. filed an 8-K on November 6, 2024, reporting other events and financial statements. The filing details the company's incorporation in Delaware and its principal executive offices located at 355 Alhambra Circle, Suite 801, Coral Gables, Florida.
Why It Matters
This 8-K filing provides an update on Catalyst Pharmaceuticals' corporate information and regulatory filings, which is important for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new information that would immediately impact the company's risk profile.
Key Numbers
- 001-33057 — SEC File Number (Company's SEC filing identifier)
- 76-0837053 — I.R.S. Employer Identification No. (Company's tax identification number)
Key Players & Entities
- CATALYST PHARMACEUTICALS, INC. (company) — Registrant
- November 6, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of incorporation
- 355 Alhambra Circle Suite 801 Coral Gables , Florida 33134 (address) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of November 6, 2024.
When was Catalyst Pharmaceuticals, Inc. incorporated?
Catalyst Pharmaceuticals, Inc. was incorporated in Delaware.
What is the company's principal executive office address?
The company's principal executive office is located at 355 Alhambra Circle, Suite 801, Coral Gables, Florida 33134.
What is the SEC file number for Catalyst Pharmaceuticals, Inc.?
The SEC file number for Catalyst Pharmaceuticals, Inc. is 001-33057.
Does this filing indicate any significant new business developments or financial changes?
This filing appears to be a routine corporate update and does not explicitly detail significant new business developments or financial changes beyond standard reporting requirements.
Filing Stats: 423 words · 2 min read · ~1 pages · Grade level 11.1 · Accepted 2024-11-06 17:10:28
Key Financial Figures
- $0.001 — Ticker Symbol Common Stock, par value $0.001 per share NASDAQ Capital Market CPR
Filing Documents
- d882968d8k.htm (8-K) — 25KB
- d882968dex991.htm (EX-99.1) — 112KB
- 0001193125-24-252194.txt ( ) — 273KB
- cprx-20241106.xsd (EX-101.SCH) — 3KB
- cprx-20241106_lab.xml (EX-101.LAB) — 18KB
- cprx-20241106_pre.xml (EX-101.PRE) — 11KB
- d882968d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits 99.1 Press release issued by the Company on November 6, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Catalyst Pharmaceuticals, Inc. By: /s/ Michael Kalb Michael Kalb Executive Vice President and CFO Dated: November 6, 2024 3